Miaoyun Long

Dr. Miaoyun Long

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YZYue Zhu
Yue Zhu
XPXinzhi Peng
Xinzhi Peng
QZQianlei Zhou
Qianlei Zhou
LTLangping Tan
Langping Tan
CZCheng Zhang
Cheng Zhang
MLMiaoyun Long
Miaoyun Long
Papillary thyroid cancer (PTC) is a common endocrine system malignancy all over the world. Aberrant expression of six transmembrane epithelial antigen of the prostate 2 (STEAP2) has been functionally associated with cancer progression in many cancers. Nevertheless, its biological function in PTC is still unclear. Here, we found that PTC tissues had preferentially downregulated STEAP2 as compared with noncancerous tissues. Low STEAP2 expression correlated with aggressive clinicopathological characteristics and dismal prognosis in patients with PTC. We performed gain- and loss-of-function experiments, including cell proliferation assay (Cell Counting Kit-8 assay), EdU (5-ethynyl-2′-deoxyuridine) and colony formation assays, transwell migration, and invasion assays, and constructed a nude mouse xenograft tumor model. The results demonstrated thatSTEAP2overexpression inhibited PTC cell proliferation, migration, and invasion in vitro and inhibited lung metastasis and tumorigenicity in vivo. Conversely, silencingSTEAP2yielded the opposite results in vitro. Mechanistically, bioinformatics analysis combined with validation experiments identifiedSTEAP2as the downstream target of methyltransferase-like 3 (METTL3)-mediated N6-methyladenosine (m6A) modification. METTL3 stabilizedSTEAP2mRNA and regulated STEAP2 expression positively in an m6A-dependent manner. We also showed that m6A-mediatedSTEAP2mRNA translation initiation relied on a pathway dependent on the m6A reader protein YTHDF1. Rescue experiments revealed that silencingSTEAP2partially rescued the tumor-suppressive phenotype induced by METTL3 overexpression. Lastly, we verified that the METTL3–STEAP2 axis functions as an inhibitor in PTC by suppressing epithelial–mesenchymal transition and the Hedgehog signaling pathway. Taken together, these findings strongly suggest that METTL3-mediatedSTEAP2m6A modification plays a critical tumor-suppressive role in PTC progression. The METTL3–STEAP2 axis may be a potential therapeutic molecular target against PTC.

11 July 2024 in International Journal of Surgery
Verified
Journal Article
Open access
YYYunfang Yu
Yunfang Yu
WOwenhao ouyang
wenhao ouyang
YHyunxi huang
yunxi huang
HHHong Huang
Hong Huang
ZWZehua Wang
Zehua Wang
MLMiaoyun Long
Miaoyun Long
Background: Papillary thyroid carcinoma (PTC) is the predominant form of thyroid cancer globally, especially when lymph node metastasis (LNM) occurs. Molecular heterogeneity, driven by genetic alterations and tumor microenvironment components, contributes to the complexity of PTC. Understanding these complexities is essential for precise risk stratification and therapeutic decisions. Methods: This study involved a comprehensive analysis of 521 patients with PTC from our hospital and 499 patients from The Cancer Genome Atlas (TCGA). The real-world cohort 1 comprised 256 patients with stage I–III PTC. Tissues from 252 patients were analyzed by DNA-based next-generation sequencing, and tissues from four patients were analyzed by single-cell RNA sequencing (scRNA-seq). Additionally, 586 PTC pathological sections were collected from TCGA, and 275 PTC pathological sections were collected from the real-world cohort 2. A deep-learning multi-modal model was developed using matched histopathology images, genomic, transcriptomic, and immune cell data to predict LNM and disease-free survival (DFS). Results: This study included a total of 1011 PTC patients, comprising 256 patients from cohort 1, 275 patients from cohort 2, and 499 patients from TCGA. In cohort 1, the authors categorized PTC into four molecular subtypes based on BRAF, RAS, RET, and other mutations. BRAF mutations were significantly associated with LNM and impacted DFS. ScRNA-seq identified distinct T-cell subtypes and reduced B-cell diversity in BRAF-mutated PTC with LNM. The study also explored cancer-associated fibroblasts and macrophages, highlighting their associations with LNM. The deep-learning model was trained using 405 pathology slides and RNA sequences from 328 PTC patients and validated with 181 slides and RNA sequences from 140 PTC patients in the TCGA cohort. It achieved high accuracy, with an area under the curve (AUC) of 0.86 in the training cohort, 0.84 in the validation cohort, and 0.83 in the real-world cohort 2. High-risk patients in the training cohort had significantly lower DFS rates ( P <0.001). Model AUCs were 0.91 at 1 year, 0.93 at 3 years, and 0.87 at 5 years. In the validation cohort, high-risk patients also had lower DFS ( P <0.001); the AUCs were 0.89, 0.87, and 0.80 at 1, 3, and 5 years. The authors utilized the GradCAM algorithm to generate heatmaps from pathology-based deep-learning models, which visually highlighted high-risk tumor areas in PTC patients. This enhanced clinicians’ understanding of the model’s predictions and improved diagnostic accuracy, especially in cases with lymph node metastasis. Conclusion: The artificial intelligence (AI)-based analysis uncovered vital insights into PTC molecular heterogeneity, emphasizing BRAF mutations’ impact. The integrated deep-learning model shows promise in predicting metastasis, offering valuable contributions to improved diagnostic and therapeutic strategies.

21 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LTLangping Tan
Langping Tan
ZHZhenjun Huang
Zhenjun Huang
YCYongjian Chen
Yongjian Chen
ZWZehua Wang
Zehua Wang
ZLZijia Lai
Zijia Lai
MLMiaoyun Long
Miaoyun Long
Background: The prognosis management of thyroid cancer remains a significant challenge. This study highlights the critical role of T cells in the tumor microenvironment and aims to improve prognostic precision by integrating bulk RNA-seq and single-cell RNA-seq (scRNA-seq) data, providing a more comprehensive view of tumor biology at the single-cell level. Method: 15 thyroid cancer scRNA-seq samples were analyzed from GEO and 489 patients from TCGA. A multi-level attention graph neural network (MLA-GNN) model was applied to integrate T-cell-related differentially expressed genes (DEGs) for predicting disease-free survival (DFS). Patients were divided into training and validation cohorts in an 8:2 ratio. Result: We systematically characterized the immune microenvironment of metastatic thyroid cancer by using single-cell transcriptomics and identified the important role of T-cell subtypes in the development of thyroid cancer. T-cell-based DEGS between tumor tissues and normal tissues were also identified. Subsequently, T-cell-based risk signatures were selected for establishing a risk model using MLA-GNN. Finally, our MLA-GNN-based model demonstrated an excellent ability to predict the DFS of thyroid cancer patients (1-year AUC: 0.965, 3-years AUC: 0.979, and 5-years AUC: 0.949 in training groups, and 1-year AUC: 0.879, 3-years AUC: 0.804, and 5-years AUC: 0.804 in validation groups). Conclusions: Risk features based on T-cell genes have demonstrated the effectiveness in predicting the prognosis of thyroid cancer. By conducting a comprehensive characterization of T-cell features, we aim to enhance our understanding of the tumor’s response to immunotherapy and uncover new strategies for the treatment of cancer.

16 May 2018 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MLMiaoyun Long
Miaoyun Long
FDFei‐Yu Diao
Fei‐Yu Diao
LPLi‐Na Peng
Li‐Na Peng
LTLang‐Ping Tan
Lang‐Ping Tan
YZYue Zhu
Yue Zhu
HLHong‐Hao Li
Hong‐Hao Li

3 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YYYisikandaer Yalikun
Yisikandaer Yalikun
YSYuxin Shen
Yuxin Shen
AMAnyun Mao
Anyun Mao
QZQianlei Zhou
Qianlei Zhou
JWJinchen Wei
Jinchen Wei
MLMiaoyun Long
Miaoyun Long
Objectives: Papillary thyroid carcinoma (PTC) frequently presents with cervical lymph node metastasis (CLNM), yet preoperative tools often encode BRAF V600E as a binary variable, potentially overlooking information contained in mutation abundance. We sought to quantify the dose–response relationship between BRAF V600E abundance and CLNM and to develop an interpretable model for preoperative risk stratification. Methods: We performed a single-center retrospective study of consecutive PTC patients who underwent preoperative BRAF V600E testing and surgery from 2019 to 2023. Patients were randomly split 70/30 into training and test sets. Candidate predictors included clinical and ultrasound features and BRAF V600E abundance. We used multivariable logistic regression and restricted cubic splines (RCS) to assess nonlinearity and compared six machine-learning algorithms (LR, KNN, SVM, XGB, LightGBM, and NN). Model performance was evaluated by F1, AUC, calibration, and decision-curve analyses; SHAP aided interpretation. Ethics approval: SYSKY-2024-169-01. Results: The cohort included 667 patients; CLNM occurred in 391 (58.6%). CLNM cases had higher BRAF abundance (median 23% vs. 17%) and characteristic clinical/sonographic differences. RCS revealed a nonlinear association between abundance and CLNM, with a steep risk rise of up to ~20.7% followed by a plateau. Among six algorithms, XGBoost showed the best validation performance (AUC 0.752; F1 0.73). SHAP indicated that maximum tumor diameter, BRAF abundance, age, and microcalcifications contributed most to predictions. Conclusions: Modeling BRAF V600E as a quantitative abundance—rather than a binary status—improves preoperative CLNM risk assessment in PTC. An interpretable XGBoost model integrating abundance with routine features demonstrates acceptable discrimination and potential clinical utility for individualized surgical planning and counseling.

9 April 2025 in Precision Clinical Medicine
Verified
Journal Article
Open access
YYYunfang Yu
Yunfang Yu
YSYuxin Shen
Yuxin Shen
YTYujie Tan
Yujie Tan
YYYisikandaer Yalikun
Yisikandaer Yalikun
TTTian Tian
Tian Tian
MLMiaoyun Long
Miaoyun Long
Objective: This prospective observational cohort real-world study evaluates and compares the efficacy and prognosis of ultrasound (US) and gene-based microwave ablation (MWA) and surgical treatment in patients with low-risk papillary thyroid carcinoma (PTC), emphasizing the influence of genetic mutations on low-risk patient selection. Background: MWA, a minimally invasive technique, is increasingly recognized in the management of PTC. While traditional criteria for ablation focus on tumor size, number, and location, the impact of genetic mutations on treatment efficacy remains underexplored. Methods: A total of 201 patients with low-risk PTC without metastasis were prospectively enrolled. All patients underwent US and next-generation sequencing to confirm low-risk status. Patients chose either ablation or surgery and were monitored until November 2024. Efficacy and complications were assessed using thyroid US and contrast-enhanced US. Results: The median follow-up of this study is 12 months. There is no significant difference between the ablation group (3.0%) and the surgery group (1.0%) in disease free survival (P = 0.360). However, the surgery group exhibited a significantly higher complication rate, particularly for temporary hypoparathyroidism (P < 0.001). Ablation offers notable advantages, including shorter treatment duration, faster recovery, less intraoperative blood loss, and reduced costs (P < 0.001), while maintaining favorable safety and comparable efficiency. Conclusions: For patients with low-risk genetic mutations, ablation provides comparable efficacy and disease free survival to surgery, with significant benefits in safety, recovery, and overall cost. Guided by US and next-generation sequencing, precise patient selection enhances the potential of ablation as a promising, minimally invasive alternative to surgery in the management of low-risk PTC .